Literature DB >> 26805662

Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs.

Adam D DeVore1, Phillip J Schulte2, Robert J Mentz3, N Chantelle Hardy4, Jacob P Kelly3, Eric J Velazquez3, Juan F Maya5, Adrian Kielhorn5, Harshali K Patel5, Shelby D Reed3, Adrian F Hernandez3.   

Abstract

There are limited data describing outcomes associated with an elevated heart rate in patients with heart failure with reduced ejection fraction (HFrEF) in routine clinical practice. We identified patients with HFrEF at Duke University Hospital undergoing echocardiograms and heart rate assessments without paced rhythms or atrial fibrillation. Outcomes (all-cause mortality or hospitalization and medical costs per day alive) were assessed using electronic medical records, hospital cost accounting data, and national death records. Patients were stratified by heart rate (<70 and ≥70 beats/min) and compared using generalized linear models specified with gamma error distributions and log links for costs and proportional hazard models for mortality/hospitalization. Of 722 eligible patients, 582 patients (81%) were treated with β blockers. The median heart rate was 81 beats/min (25th and 75th percentiles 69 to 96) and 527 patients (73%) had a heart rate ≥70 beats/min. After multivariate adjustment, a heart rate ≥70 beats/min was associated with increased 1-year all-cause mortality or hospitalization, hazard ratio 1.37 (95% CI 1.07 to 1.75) and increased medical costs per day alive, cost ratio 2.03 (95% CI 1.53 to 2.69). In conclusion, at a large tertiary care center, despite broad use of β blockers, a heart rate ≥70 beats/min was observed in 73% of patients with HFrEF and associated with worse 1-year outcomes and increased direct medical costs per day alive.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26805662      PMCID: PMC5429586          DOI: 10.1016/j.amjcard.2015.12.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

1.  EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).

Authors:  Aldo P Maggioni; Ulf Dahlström; Gerasimos Filippatos; Ovidiu Chioncel; Marisa Crespo Leiro; Jaroslaw Drozdz; Friedrich Fruhwald; Lars Gullestad; Damien Logeart; Marco Metra; John Parissis; Hans Persson; Piotr Ponikowski; Mathias Rauchhaus; Adriaan Voors; Olav Wendelboe Nielsen; Faiez Zannad; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2010-08-29       Impact factor: 15.534

2.  The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics.

Authors:  Richard Lowrie; Frances S Mair; Nicola Greenlaw; Paul Forsyth; Alex McConnachie; Janice Richardson; Nina Khan; Deborah Morrison; Claudia-Martina Messow; Brian Rae; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2011-08       Impact factor: 15.534

3.  Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?

Authors:  Jennifer Franke; Jan Sebastian Wolter; Lillian Meme; Jeannette Keppler; Ramon Tschierschke; Hugo A Katus; Christian Zugck
Journal:  Clin Res Cardiol       Date:  2012-07-04       Impact factor: 5.460

4.  Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.

Authors:  Douglas H Elder; Mohapradeep Mohan; Lynda Cochrane; Helena Charles; Chim C Lang
Journal:  Cardiovasc Ther       Date:  2015-06       Impact factor: 3.023

5.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

6.  Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation.

Authors:  Anh L Bui; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Clyde W Yancy; Deepak L Bhatt; Gregg C Fonarow
Journal:  Am Heart J       Date:  2013-02-16       Impact factor: 4.749

7.  The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Jane E Wilcox; Matthew E Harinstein; Aldo P Maggioni; Haris Subacius; Faiez Zannad; Marvin A Konstam; Ovidiu Chioncel; Clyde W Yancy; Karl Swedberg; Javed Butler; Robert O Bonow; Mihai Gheorghiade
Journal:  JACC Heart Fail       Date:  2013-12-02       Impact factor: 12.035

8.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.

Authors:  Davide Castagno; Hicham Skali; Madoka Takeuchi; Karl Swedberg; Salim Yusuf; Christopher B Granger; Eric L Michelson; Marc A Pfeffer; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2012-05-15       Impact factor: 24.094

9.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.

Authors:  Aldo P Maggioni; Stefan D Anker; Ulf Dahlström; Gerasimos Filippatos; Piotr Ponikowski; Faiez Zannad; Offer Amir; Ovidiu Chioncel; Marisa Crespo Leiro; Jaroslaw Drozdz; Andrejs Erglis; Emir Fazlibegovic; Candida Fonseca; Friedrich Fruhwald; Plamen Gatzov; Eva Goncalvesova; Mahmoud Hassanein; Jaromir Hradec; Ausra Kavoliuniene; Mitja Lainscak; Damien Logeart; Bela Merkely; Marco Metra; Hans Persson; Petar Seferovic; Ahmet Temizhan; Dimitris Tousoulis; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2013-08-26       Impact factor: 15.534

10.  Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization.

Authors:  Warren K Laskey; Ihab Alomari; Margueritte Cox; Phillip J Schulte; Xin Zhao; Adrian F Hernandez; Paul A Heidenreich; Zubin J Eapen; Clyde Yancy; Deepak L Bhatt; Gregg C Fonarow
Journal:  J Am Heart Assoc       Date:  2015-04-22       Impact factor: 5.501

View more
  7 in total

Review 1.  Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Authors:  Shi Yin Wong; Ainsley Ryan Yan Bin Lee; Aaron Hon Jiun Sia; Yu Jun Wo; Yao Hao Teo; Yao Neng Teo; Nicholas L Syn; Ching-Ching Ong; Lynette L Teo; Tiong-Cheng Yeo; Kian-Keong Poh; William K Kong; Raymond C Wong; Ching-Hui Sia
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-12       Impact factor: 3.947

2.  Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction.

Authors:  Xiaotong Cui; Erik Thunström; Ulf Dahlström; Jingmin Zhou; Junbo Ge; Michael Fu
Journal:  ESC Heart Fail       Date:  2020-07-30

3.  Is Current Drug Therapy for Heart Failure Sufficient to Control Heart Rate of Patients?

Authors:  Juliano Cardoso; Mateus Dressler de Espíndola; Mauricio Cunha; Enock Netto; Cristina Cardoso; Milena Novaes; Carlos Henrique Del Carlo; Euler Brancalhão; Alessandro Lyra Name; Antonio Carlos Pereira Barretto
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

Review 4.  The potential of glucagon-like peptide-1 receptor agonists in heart failure.

Authors:  Frederik Flindt Kreiner; G Kees Kornelis Hovingh; Bernt Johan von Scholten
Journal:  Front Physiol       Date:  2022-09-20       Impact factor: 4.755

5.  The Effect of Ivabradine on the Human Atrial Myocardial Contractility in an In Vitro Study.

Authors:  Ryan Chaban; Katja Buschmann; Anna Krausgrill; Andres Beiras-Fernandez; Christian-Friedrich Vahl
Journal:  Cardiol Res Pract       Date:  2019-10-30       Impact factor: 1.866

6.  Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers.

Authors:  Kenneth D Varian; Xinge Ji; Justin L Grodin; Frederik H Verbrugge; Alex Milinovich; Michael W Kattan; W H Wilson Tang
Journal:  ESC Heart Fail       Date:  2020-08-05

7.  The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients.

Authors:  Chia-Te Liao; Jin-Long Huang; Huai-Wen Liang; Fa-Po Chung; Ying-Hsiang Lee; Po-Lin Lin; Wei-Ru Chiou; Wen-Yu Lin; Chien-Yi Hsu; Hung-Yu Chang
Journal:  ESC Heart Fail       Date:  2021-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.